Neoadjuvant chemotherapy in cervical cancer: an update

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86
   PubMed Web of Science ®Google Scholar
• Whitney CW, Sause W, Bundy BN, et al. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999;17:1339-48
   PubMed Web of Science ®Google Scholar
• Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: a randomized radiation therapy oncology group clinical trial. N Engl J Med 1999;340:1137-43
   PubMed Web of Science ®Google Scholar
• Peters WA III, Liu PY, Barrett RJ, et al. Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a phase III intergroup study. J Clin Oncol 2000;18:1606-13
   PubMed Web of Science ®Google Scholar
• Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based chemoradiation improves progression free and overall survival in advanced cervical cancer: Results of a randomized Gynecologic Oncology Group Study. N Engl J Med 1999;340:1144-53
   PubMed Web of Science ®Google Scholar
• Keys HM, Bundy BM, Stehman FB, et al. A comparison of weekly cisplatin during radiation therapy versus irradiation alone each followed by adjuvant hysterectomy in bulky stage IB cervical carcinoma: A randomized trial of the gynecologic oncology group. N Engl J Med 1999;340:1154-61
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. National Cancer Institute: NCI Clinical Announcement. Department of Health and Human Services, Public Health Service. Bethesda, MD, USA; 1999
   Google Scholar
• Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 2001;358:781-6
   PubMed Web of Science ®Google Scholar
• Benedetti Panici P, Greggi S, Scambia G. Long term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Eur J of Canc 1998;34:341-6
   PubMed Web of Science ®Google Scholar
• Sardi JE, Di Paola GR, Cachau A, et al. A possible new trend in the management of the carcinoma of the cervix uteri. Gyn Onc 1986;25:139-49
   PubMed Web of Science ®Google Scholar
• Paladini D, Raspagliesi F, Fontanelli R, et al. Radical surgery after induction chemotherapy in locally advanced cervical cancer. A feasibility study. Int J Gynecol Cancer 1995;5(4):296-300
   PubMed Web of Science ®Google Scholar
• Friedlander M, Kaye SB, Sullivan A, et al. Cervical carcinoma: a drug-responsive tumor-experience with combined cisplatin, vinblastine and bleomycin therapy. Gyn Oncol 1983;16:275-81
   PubMed Web of Science ®Google Scholar
• Benedetti Panici PG, Scambia G, Baiocchi G, et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival. Cancer 1991;15:372-9
   Web of Science ®Google Scholar
• Deppe G, Malviya VK, Han I, et al. A preliminary report of combination chemotherapy with cisplatin and mitomycin-C followed by radical hysterectomy or radiation therapy in patients with locally advanced cervical cancer. Gynecol Oncol 1991;42:178-81
   PubMed Web of Science ®Google Scholar
• Chang HC, Lai CH, Chou PC, et al. Neoadjuvant chemotherapy with cisplatin, vincristine, and bleomycin and radical surgery in early-stage bulky cervical carcinoma. Cancer Chemother Pharmacol 1992;30:281-5
   PubMed Web of Science ®Google Scholar
• Zanetta G, Landoni F, Colombo A, et al. Three-year results after neoadjuvant chemotherapy, radical surgery, and radiotherapy in locally advanced cervical carcinoma. Obstet Gynecol 1993;82:447-50
   PubMed Web of Science ®Google Scholar
• Souhami L, Gil RA, Allan SE, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 1991;9(6):970-7
   PubMed Web of Science ®Google Scholar
• Chauvergne J, Lhommé C, Rohart J, et al. Neoadjuvant chemotherapy of stage IIB or III cancers of the uterine cervix. Long-term results of a multicenter randomized trial of 151 patients. Bull Cancer 1993;80:1069-79
   PubMed Web of Science ®Google Scholar
• Tattersall MH, Lorvidhaya V, Vootiprux V, et al. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. cervical cancer study group of the Asian Oceanian Clinical Oncology Association. J Clin Oncol 1995;13(2):444-51
   PubMed Web of Science ®Google Scholar
• Kumar L, Grover R, Pokharel YH, et al. Neoadjuvant chemotherapy in locally advanced cervical cancer: two randomised studies. Aust N Z J Med 1998;28:387-90
   PubMedGoogle Scholar
• Herod J, Burton A, Buxton J, et al. A randomized prospective phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in operable cancer of the cervix. Ann Oncol 2000;11:1175-81
   PubMed Web of Science ®Google Scholar
• Symonds RP, Habeshaw T, Reed NS, et al. The Scottish and Manchester randomized trial of neo-adjuvant chemotherapy for advanced cervical cancer. Eur J Cancer 2000;36:994-1001
   PubMed Web of Science ®Google Scholar
• Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer 2003;39:2470-86
   PubMed Web of Science ®Google Scholar
• Rew DA, Wilson GD. Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J of Surg Oncol 2000;26:405-17
   PubMed Web of Science ®Google Scholar
• Bolger BS, Sysmonds RP, Stanton PD, et al. Prediction of radiotherapy response of cervical carcinoma through measurement of proliferation rate. Br J Cancer 1996;74:1223-6
   PubMed Web of Science ®Google Scholar
• Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis Collaboration (NACCCMA) Collaboration. Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst Rev 2004(2):CD001774
   Google Scholar
• Sardi J, Sananes C, Giaroli A, et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage Ib, bulky, squamous carcinoma of the cervix. Gynecol Oncol 1993;49:156-65
   PubMed Web of Science ®Google Scholar
• Benedetti Panici PL, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 2002;20:179-88
   PubMed Web of Science ®Google Scholar
• Lanciano RM, Pajak TF, Martz K, Hanks GE. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study. Int J Radiat Oncol Biol Phys 1993;25:391-7
   PubMed Web of Science ®Google Scholar
• Chang C, Lai CH, Hong JH, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy vs. radiation therapy for bulky stage Ib and IIA cervical cancer. J Clin Oncol 2000;18:1740-7
   PubMed Web of Science ®Google Scholar
• Kigawa J, Minagawa Y, Ishihara H, et al. The role of neoadjuvant intra-arterial infusion chemotherapy with cisplatin and bleomycin for locally advanced cervical cancer. Am J Clin Onc 1996;19:255-9
   PubMed Web of Science ®Google Scholar
• Sardi J, Giaroli A, Sananes C, et al. Randomized trial with neoadjuvant chemotherapy in stage IIIB squamous carcinoma cervix uteri: an unexpected therapeutic management. Int J Gynecol Canc 1996;6:85-93
   Web of Science ®Google Scholar
• Sardi JE, Sananes CE, Giaroli A, et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. Int J Gynecol Canc 1998;8:441-50
   Web of Science ®Google Scholar
• Chemotherapy followed by surgery vs radiotherapy plus chemotherapy in patients with Stage IB or II cervical cancer. Available from: http:// ClinicalTrials.gov Identifier: NCT00039338/EORTC55994
   Google Scholar
• Sardi JE, Giaroli A, Sananes C, et al. Long-term follow up of the first randomized trial using neoadjuvant chemotherapy in stage IB squamous carcinoma of the cervix: The final results. Gynecol Oncol 1997;67(1):61-9
   PubMed Web of Science ®Google Scholar
• Cai HB, Chen HZ, Yin HH. Randomized study of preoperative chemotherapy versus primary surgery for stage IB cervical cancer. J Obstet Gynecol Res 2006;32(3):315-23
   Web of Science ®Google Scholar
• Napolitano U, Imperato F, Mossa B, et al. The role of neoadjuvant chemotherapy for squamous cell cervical cancer (Ib-IIIB): A long-term randomized trial. Eur J Gynecol Oncol 2003;24(1):51-9
   PubMed Web of Science ®Google Scholar
• Chen H, Liang C, Zhang L, et al. Clinical efficacy of modified pre-operative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: Randomized study. Gynecol Oncol 2008;110(3):308-15
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yoshikawa H, Kobayashi H, et al. Japan Clinical Oncology Group. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical hysterectomy versus radical surgery alone for stages IB2, IIA2 and IIB cervical cancer: A Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer 2013;108(10):1957-63
   PubMed Web of Science ®Google Scholar
• Eddy GL, Bundy BN, Creasman WT, et al. Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of Gynecologic Oncology Group. Gynecon Oncol 2007;106(2):362-9
   PubMed Web of Science ®Google Scholar
• Rydzewska L, Tierney J, Vale CL, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2012;12:CD007406
   PubMed Web of Science ®Google Scholar
• Kim HS, Sardi JE, Katsumata N, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: An international collaborative meta-analysis. Eur J Surg Oncol 2013;39:115-24
   PubMed Web of Science ®Google Scholar
• Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 1997;15:165-71
   PubMed Web of Science ®Google Scholar
• McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996;14:792-5
   PubMed Web of Science ®Google Scholar
• Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2004;22:3113-19
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MV, McMeekin DS, et al. Phase III trial of four cisplatin – containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55
   PubMed Web of Science ®Google Scholar
• Kitagawa R, Katsumata N, Fukuda H, et al. A randomized phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). J Clin Oncol 2012;30(Suppl):Abstract 5006
   Google Scholar
• Park DC, Suh MJ, Yeo SG. Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: Long-term results. Int J Gynecol Canc 2009;19:943-7
   PubMed Web of Science ®Google Scholar
• Zanetta G, Lissoni A, Pellegrino A, et al. Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer. Ann Oncol 1998;9:977-08
   PubMed Web of Science ®Google Scholar
• Buda A, Fossati R, Colombo N, et al. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol 2005;23:4137-45
   PubMed Web of Science ®Google Scholar
• Lissoni AA, Colombo N, Pellegrino A, et al. A phase II randomized trial of neoadjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patient with locally advanced squamous cell cervical carcinoma: the SNAP-02 Italian Collaborative Study. Ann Oncol 2009;20:660-5
   PubMed Web of Science ®Google Scholar
• Duenas-Gonzales A, Lopez-Graniel C, González-Enciso A, et al. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. Ann Oncol 2003;14:1278-84
   PubMed Web of Science ®Google Scholar
• Angioli R, Plotti F, Luvero D, et al. Feasibility and safety of carboplatin plus paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: a pilot study. Tumour Biol 2014;35:2741-6
   PubMed Web of Science ®Google Scholar
• Markman M. Weekly paclitaxel in the management of ovarian cancer. Semin Oncol 2000;27:37-40
   PubMed Web of Science ®Google Scholar
• Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-71
   PubMed Web of Science ®Google Scholar
• Schuette W, Blankenburg T, Guschall W, et al. Multicenter phase III trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin. Clin Lung Cancer 2006;7:338-43
   PubMed Web of Science ®Google Scholar
• Belani CP, Ramalingam S, Perry MC, et al. Randomized phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-week administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol 2008;26:468-73
   PubMed Web of Science ®Google Scholar
• Katsumata N, Yasuda M, Takahashi F, et al. Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3 open-label randomized controlled trial. Lancet 2009;374:1331-8
   PubMed Web of Science ®Google Scholar
• Mori T, Kinoshita Y, Watanabe A, et al. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol 2006;58:665-72
   PubMed Web of Science ®Google Scholar
• Mori T, Hosokawa K, Sawada M, et al. Neoadjuvant weekly carboplatin and paclitaxel followed by radical hysterectomy for locally advanced cervical cancer: long-term results. Int J Gynecol Cancer 2010;20:611-16
   PubMed Web of Science ®Google Scholar
• McCormack M, Kadalayil L, Hackshaw A, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer 2013;108:2464-9
   PubMed Web of Science ®Google Scholar
• Singh RB, Chander S, Mohanti BK, et al. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study. Gynecol Oncol 2013;129:124-8
   PubMed Web of Science ®Google Scholar
• Induction chemotherapy plus chemoradiation as first line treatment for locally advanced cervical cancer (INTERLACE). Available from: https://clinicaltrials.gov/ct2/show/NCT01566240
   Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-19
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol 2009;27(7):1069-74
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJIII, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734-43
   PubMed Web of Science ®Google Scholar
• Schefter T, Winter K, Kwon JS, et al. RTOG: 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys 2014;88:101-5
   PubMed Web of Science ®Google Scholar
• Symonds P, Gourley C, Davidson S, et al. CIRCCa: A randomized double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. Ann Oncol 2014;25(5):1-41
   Google Scholar